NLS Pharmaceutics and Kadimastem Receive Hong Kong Patent for Diabetes Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 04 2025
0mins
Patent Grant: Kadimastem has received a patent from the Hong Kong Intellectual Property Department for its proprietary cell selection and enrichment technology related to IsletRx, a therapy for insulin-dependent diabetes.
Global Protection: This new patent complements existing patents in Europe, the United States, and India, enhancing the global protection of IsletRx and its therapeutic potential.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
